糖类抗原125和血清激肽释放酶10在上皮性卵巢癌中的表达

Serum level of CA125 and hk10 in patients with ovarian cancer

目的探讨血清糖类抗原125(CA125)和激肽释放酶10(hk10)在上皮性卵巢癌中的表达及其在紫杉醇联合顺铂(TP)化疗方案疗效评估中的作用。方法 36例上皮性卵巢癌患者第1天24 h静脉滴注紫杉醇135 mg·m-2,第2,3天静脉滴注顺铂75 mg·m-2。酶联免疫吸附法(ELISA)检测36例上皮性卵巢癌患者及27例良性卵巢肿瘤患者血清CA125及hk10水平,分析2组患者CA125、hk10水平。同时检测28例卵巢癌患者TP化疗前后CA125和hk10水平变化及其与化疗疗效的相关性。结果卵巢癌组患者血清CA125及hk10水平显著高于良性卵巢肿瘤组(P均<0.05)。28例卵巢癌患者接受TP方案化疗,完全缓解(CR)4例,部分缓解(PR)11例,稳定(SD)3例,进展(PD)10例,客观缓解率为64.3%。CR组化疗后CA125及hk10水平显著低于SD及PD组(P<0.05)。结论卵巢癌患者血清CA125和hk10水平显著升高,可以作为TP方案化疗疗效的评估指标。

Objective To investigate the serum level of CA125 and hk10 in patients with ovarian cancer and the value as biomarker for paclitaxel combined cisplatin（ TP） chemotherapy. Methods Thirty- six patients with ovarian cancer were given paclitaxel 135 mg · m^-2 for 24 hours on the first day and cisplatin 75 mg ·m^-2 on the first and second day through intravenous infusion. The data of serum level of CA125 and hk10 in patients with ovarian cancer（ n = 36） and benign ovarian tumor（ n = 27） were tested by ELISA method and then were compared. The data of serum level of CA125 and hk10 and their relationship with chemotherapy was also tested in 28 ovarian tumor cancer patients receiving TP chemotherapy. After TP chemotherapy,CR,PR,SD and PD to assess the relationship between CA125, hk10 and chemotherapy efficacy.Results In the ovarian tumor cancer group,the serum levels of CA125 and hk10 were significantly higher than those in benign ovarian tumor group（ P〈0. 05） and 4 cases of complete response（ CR）,11 cases of partial response（ PR）,3 cases of stable disease（ SD）,and 10 cases of progress disease（ PD） were achieved,with an objective response rate of64. 3%. The level of CA125 and hk10 in CR group were significantly lower than those in SD and PD groups（ P〈0. 05）. Conclusion Serum level of CA125 and hk10 were elevated in ovarian cancer patients andcould be the biomarkers for chemotherapy prognosis.